undertaken the minimum investigations required to establish the diagnosis of this uncommon lymphoma. This is of particular concern as the disease presentation in their patient was atypical.
The patient's disease progressed despite treatment with cyclophosphamide and prednisolone. In spite of his age and other symptoms (neuropathy, epistaxis and pulmonary disease), no further chemotherapy was administered. Long-term remissions have only been reported in 50% of patients treated with cyclophosphamide and prednisolone. 8 The use of Adriamycin-containing chemotherapy regimens has produced long-term survivors amongst patients presenting with aggressive diease.9"00 This option should have been considered in this patient.
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